iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.

A major challenge in the management of patients with prostate cancer is identifying those individuals at risk of developing metastatic disease, as in most cases the disease will remain indolent. We analyzed pooled serum samples from 4 groups of patients (n = 5 samples/group), collected prospectively...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ishtiaq Rehman, Caroline A Evans, Adam Glen, Simon S Cross, Colby L Eaton, Jenny Down, Giancarlo Pesce, Joshua T Phillips, Ow Saw Yen, George N Thalmann, Phillip C Wright, Freddie C Hamdy
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7a4c7d04ad2d482c8657cbddab3a930d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7a4c7d04ad2d482c8657cbddab3a930d
record_format	dspace
spelling	oai:doaj.org-article:7a4c7d04ad2d482c8657cbddab3a930d2021-11-18T07:28:14ZiTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.1932-620310.1371/journal.pone.0030885https://doaj.org/article/7a4c7d04ad2d482c8657cbddab3a930d2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22355332/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203A major challenge in the management of patients with prostate cancer is identifying those individuals at risk of developing metastatic disease, as in most cases the disease will remain indolent. We analyzed pooled serum samples from 4 groups of patients (n = 5 samples/group), collected prospectively and actively monitored for a minimum of 5 yrs. Patients groups were (i) histological diagnosis of benign prostatic hyperplasia with no evidence of cancer 'BPH', (ii) localised cancer with no evidence of progression, 'non-progressing' (iii) localised cancer with evidence of biochemical progression, 'progressing', and (iv) bone metastasis at presentation 'metastatic'. Pooled samples were immuno-depleted of the 14 most highly abundant proteins and analysed using a 4-plex iTRAQ approach. Overall 122 proteins were identified and relatively quantified. Comparisons of progressing versus non-progressing groups identified the significant differential expression of 25 proteins (p<0.001). Comparisons of metastatic versus progressing groups identified the significant differential expression of 23 proteins. Mapping the differentially expressed proteins onto the prostate cancer progression pathway revealed the dysregulated expression of individual proteins, pairs of proteins and 'panels' of proteins to be associated with particular stages of disease development and progression. The median immunostaining intensity of eukaryotic translation elongation factor 1 alpha 1 (eEF1A1), one of the candidates identified, was significantly higher in osteoblasts in close proximity to metastatic tumour cells compared with osteoblasts in control bone (p = 0.0353, Mann Whitney U). Our proteomic approach has identified leads for potentially useful serum biomarkers associated with the metastatic progression of prostate cancer. The panels identified, including eEF1A1 warrant further investigation and validation.Ishtiaq RehmanCaroline A EvansAdam GlenSimon S CrossColby L EatonJenny DownGiancarlo PesceJoshua T PhillipsOw Saw YenGeorge N ThalmannPhillip C WrightFreddie C HamdyPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 2, p e30885 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ishtiaq Rehman Caroline A Evans Adam Glen Simon S Cross Colby L Eaton Jenny Down Giancarlo Pesce Joshua T Phillips Ow Saw Yen George N Thalmann Phillip C Wright Freddie C Hamdy iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
description	A major challenge in the management of patients with prostate cancer is identifying those individuals at risk of developing metastatic disease, as in most cases the disease will remain indolent. We analyzed pooled serum samples from 4 groups of patients (n = 5 samples/group), collected prospectively and actively monitored for a minimum of 5 yrs. Patients groups were (i) histological diagnosis of benign prostatic hyperplasia with no evidence of cancer 'BPH', (ii) localised cancer with no evidence of progression, 'non-progressing' (iii) localised cancer with evidence of biochemical progression, 'progressing', and (iv) bone metastasis at presentation 'metastatic'. Pooled samples were immuno-depleted of the 14 most highly abundant proteins and analysed using a 4-plex iTRAQ approach. Overall 122 proteins were identified and relatively quantified. Comparisons of progressing versus non-progressing groups identified the significant differential expression of 25 proteins (p<0.001). Comparisons of metastatic versus progressing groups identified the significant differential expression of 23 proteins. Mapping the differentially expressed proteins onto the prostate cancer progression pathway revealed the dysregulated expression of individual proteins, pairs of proteins and 'panels' of proteins to be associated with particular stages of disease development and progression. The median immunostaining intensity of eukaryotic translation elongation factor 1 alpha 1 (eEF1A1), one of the candidates identified, was significantly higher in osteoblasts in close proximity to metastatic tumour cells compared with osteoblasts in control bone (p = 0.0353, Mann Whitney U). Our proteomic approach has identified leads for potentially useful serum biomarkers associated with the metastatic progression of prostate cancer. The panels identified, including eEF1A1 warrant further investigation and validation.
format	article
author	Ishtiaq Rehman Caroline A Evans Adam Glen Simon S Cross Colby L Eaton Jenny Down Giancarlo Pesce Joshua T Phillips Ow Saw Yen George N Thalmann Phillip C Wright Freddie C Hamdy
author_facet	Ishtiaq Rehman Caroline A Evans Adam Glen Simon S Cross Colby L Eaton Jenny Down Giancarlo Pesce Joshua T Phillips Ow Saw Yen George N Thalmann Phillip C Wright Freddie C Hamdy
author_sort	Ishtiaq Rehman
title	iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
title_short	iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
title_full	iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
title_fullStr	iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
title_full_unstemmed	iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
title_sort	itraq identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/7a4c7d04ad2d482c8657cbddab3a930d
work_keys_str_mv	AT ishtiaqrehman itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT carolineaevans itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT adamglen itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT simonscross itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT colbyleaton itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT jennydown itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT giancarlopesce itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT joshuatphillips itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT owsawyen itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT georgenthalmann itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT phillipcwright itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer AT freddiechamdy itraqidentificationofcandidateserumbiomarkersassociatedwithmetastaticprogressionofhumanprostatecancer
_version_	1718423417429950464

iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.

Ejemplares similares